Celcuity

Celcuity Net Tangible Assets

The Net Tangible Assets of Celcuity (CELC) as of Nov 11, 2026 is 100.56 M USD. In the previous year, Net Tangible Assets was 115.62 M USD — a change of -13.03% (lower).

Net Tangible Assets

100.56 MUSD

YoY

-13.03%

Last updated:

Net Tangible Assets of Celcuity is 2025 100.56 M USD. Net Tangible Assets of Celcuity was 2024 115.62 M USD. It decreases by -13.03% lower compared to the previous year.

The Celcuity Net Tangible Assets history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Net Tangible Assets
Date
Net Tangible Assets
Jan 1, 2018
25.35 M USD
Jan 1, 2019
19.30 M USD
Jan 1, 2020
11.70 M USD
Jan 1, 2021
68.71 M USD
Jan 1, 2022
133.77 M USD
Jan 1, 2023
139.77 M USD
Jan 1, 2024
115.62 M USD
Jan 1, 2025
100.56 M USD
The Celcuity Net Tangible Assets history
YEARNet Tangible AssetsYoY
100.56 MUSD-13.03%
115.62 MUSD-17.28%
139.77 MUSD+4.48%
133.77 MUSD+94.69%
68.71 MUSD+487.16%
11.70 MUSD-39.36%
19.30 MUSD-23.87%
25.35 MUSD-19.25%
31.39 MUSD+459.40%
5.61 MUSD+11.86%
5.02 MUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Celcuity Stock analysis

What does Celcuity do? Celcuity Inc is a biotechnology company founded by Brian Sullivan in 2012. The company is headquartered in Minneapolis, USA. The business model of Celcuity is based on researching and developing new diagnostic and treatment methods for various types of cancer. The company utilizes a proprietary technology platform called CELx, which enables the analysis of cancer cell signaling pathways and the development of individualized treatment strategies. Celcuity specializes in the development of diagnostics and personalized therapies based on individual cancer cell signaling pathways. The company operates in two divisions: 1. Diagnostics division: Celcuity's diagnostics division focuses on identifying new cancer markers and biomarkers for early detection of cancer and the development of individualized treatment strategies. 2. Therapy division: Celcuity's therapy division specializes in the development of personalized therapies based on individual cancer cell signaling pathways. Celcuity currently offers two products based on the CELx technology platform: 1. CELx HUB: CELx HUB is a cloud-based software that allows doctors and researchers to analyze cancer samples and develop individualized treatment strategies. 2. CELx TIL: CELx TIL is a diagnostic tool that measures the presence of tumor cells in the immune system of cancer patients. In summary, Celcuity Inc is a leader in the field of personalized cancer therapy based on individual cancer cell signaling pathways. The company has found a niche in this growing market and has a unique technology platform that allows it to serve its customers effectively. With its products and services, Celcuity is helping to revolutionize cancer treatment and improve the quality of life for cancer patients worldwide. Celcuity is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Celcuity stock

Net Tangible Assets of Celcuity is 100.56 M USD in 2025.

Net Tangible Assets of Celcuity changed from 115.62 M USD to 100.56 M USD, representing a -13.03% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Net Tangible Assets Celcuity since 2006 – with annual values, charts, and detailed analysis.

Net tangible assets equal total assets minus intangible assets, goodwill, and liabilities. They represent the physical asset backing of a company.

Net Tangible Assets's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Net Tangible Assets's Celcuity historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Celcuity

All Key Metrics — Celcuity